Close Menu

NEW YORK (GenomeWeb) – Illumina said today that an expanded version of its VeriSeq NIPT software to analyze fetal aneuploidies has met the requirements of the EU's in vitro diagnostic directive and it will apply the CE mark to the software.

The VeriSeq NIPT test is a noninvasive prenatal test that analyzes fetal aneuploidy for chromosomes 21, 18, 13, as well as the sex chromosomes.

The updated software includes a new method for processing samples and an increase in the number of samples it can batch from 16 to 48.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.